Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval
June 10, 2024 03:00 ET
|
Amber Therapeutics
US approval would make Amber-UI the first fully implantable adaptive neuromodulation therapy for women with mixed urinary incontinence (MUI)By targeting the pudendal nerve, Amber-UI has the unique...
Distributor Orders Nexstim NBS System 5 for European Hospital
June 10, 2024 02:00 ET
|
Nexstim Oyj
Press release, Helsinki, 10 June 2024 at 9 AM (EEST) Distributor Orders Nexstim NBS System 5 for European Hospital Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS...
Sisäpiiritieto: Nexstim Oyj tiedottaa suunnitellusta yhteistyöstä Sinaptica Therapeutics, Inc:n kanssa Alzheimerin taudin hoidon alalla
June 07, 2024 02:00 ET
|
Nexstim Oyj
Yhtiötiedote, Helsinki, 07.06.2024 klo. 9.00 (EEST) Sisäpiiritieto: Nexstim Oyj tiedottaa suunnitellusta yhteistyöstä Sinaptica Therapeutics, Inc:n kanssa Alzheimerin taudin hoidon alalla Nexstim...
Insider Information: Nexstim Plc Announces Planned Alzheimer’s Collaboration with Sinaptica Therapeutics, Inc.
June 07, 2024 02:00 ET
|
Nexstim Oyj
Company announcement, Helsinki, 7 June 2024 at 9 AM (EEST) Insider Information: Nexstim Plc Announces Planned Alzheimer’s Collaboration with Sinaptica Therapeutics, Inc. Nexstim Plc (NXTMH:HEX)...
UPDATE: New Study Investigating the Therapeutic Uses of ExaStim® Among Individuals with Cerebral Palsy
June 06, 2024 15:03 ET
|
ANEUVO
Los Angeles, CA, June 06, 2024 (GLOBE NEWSWIRE) -- In Georgetown, Texas, a 14-year-old boy defies the odds simply by walking a flight of stairs unassisted. Thanks partly to spinal stimulation...
PathMaker Neurosystems Announces $2.16 Million Award from U.S. Department of Defense for ALS Clinical Trial
June 05, 2024 06:00 ET
|
PathMaker Neurosystems Inc.
PathMaker Neurosystems receives $2.16 million award from United States Department of Defense for an expanded ALS clinical trial of its MyoRegulator device
Global Neuromodulation Devices Market Set to Double by 2030: Spinal Cord Stimulation (SCS) Applications Dominate
May 14, 2024 09:36 ET
|
Research and Markets
Dublin, May 14, 2024 (GLOBE NEWSWIRE) -- The "Neuromodulation Devices Market Size and Forecasts 2020 - 2030, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By...
Finnish Hospital Orders Nexstim NBS System 5
May 08, 2024 02:00 ET
|
Nexstim Oyj
Press release, Helsinki, 8 May 2024 at 9 AM (EEST) Finnish Hospital Orders Nexstim NBS System 5 Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from a...
Amber Therapeutics announces positive preliminary results from its first-in-human investigation of Amber-UI, its new adaptive implanted pudendal neuromodulation system for urinary incontinence
February 27, 2024 09:00 ET
|
Amber Therapeutics
Key initial results from AURA-2 study highlight good safety and scalability of Amber-UI therapy A strong efficacy signal was seen in the form of complete resolution of incontinence episodes six months...
Neuromodulation Market is Expected to Reach $11.0 Billion | MarketsandMarkets™
February 22, 2024 07:30 ET
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Neuromodulation market in terms of revenue was estimated to be worth $6.2 billion in 2023 and is poised to reach $11.0 billion by 2028, growing at a CAGR...